CVS Health Corporation (NYSE:CVS) had its price target cut by Citigroup Inc. from $87.00 to $74.00 in a research note published on Friday morning. They currently have a neutral rating on the pharmacy operator’s stock.

A number of other research firms also recently weighed in on CVS. Royal Bank Of Canada initiated coverage on CVS Health Corporation in a research report on Tuesday, September 19th. They set an outperform rating and a $95.00 target price for the company. Robert W. Baird restated a hold rating and set a $77.00 target price on shares of CVS Health Corporation in a research report on Friday, October 27th. Loop Capital initiated coverage on CVS Health Corporation in a research report on Thursday, August 24th. They set a hold rating and a $83.00 target price for the company. Jefferies Group LLC set a $86.00 target price on CVS Health Corporation and gave the stock a hold rating in a research report on Wednesday, October 18th. Finally, Wolfe Research downgraded CVS Health Corporation from an outperform rating to a market perform rating and dropped their target price for the stock from $89.00 to $82.00 in a research report on Monday, August 14th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and fifteen have assigned a buy rating to the stock. CVS Health Corporation presently has an average rating of Buy and a consensus price target of $87.33.

CVS Health Corporation (CVS) opened at $66.80 on Friday. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.09 and a quick ratio of 0.56. The company has a market capitalization of $67,910.00, a price-to-earnings ratio of 11.84, a price-to-earnings-growth ratio of 1.26 and a beta of 0.86. CVS Health Corporation has a one year low of $66.45 and a one year high of $84.72.

CVS Health Corporation (NYSE:CVS) last posted its quarterly earnings data on Monday, November 6th. The pharmacy operator reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.01. The company had revenue of $46.18 billion for the quarter, compared to analyst estimates of $46.17 billion. CVS Health Corporation had a return on equity of 17.47% and a net margin of 2.93%. The business’s revenue was up 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.64 earnings per share. sell-side analysts expect that CVS Health Corporation will post 5.88 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.watchlistnews.com/citigroup-inc-lowers-cvs-health-corporation-cvs-price-target-to-74-00/1684942.html.

The firm also recently declared a quarterly dividend, which was paid on Friday, November 3rd. Shareholders of record on Tuesday, October 24th were issued a $0.50 dividend. The ex-dividend date of this dividend was Monday, October 23rd. This represents a $2.00 annualized dividend and a dividend yield of 2.99%. CVS Health Corporation’s dividend payout ratio (DPR) is currently 41.32%.

In other news, CFO David M. Denton sold 237,078 shares of the company’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $79.65, for a total transaction of $18,883,262.70. Following the completion of the transaction, the chief financial officer now directly owns 141,096 shares of the company’s stock, valued at $11,238,296.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Helena Foulkes sold 39,340 shares of the company’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $81.88, for a total value of $3,221,159.20. Following the transaction, the executive vice president now directly owns 84,337 shares of the company’s stock, valued at $6,905,513.56. The disclosure for this sale can be found here. Insiders sold 716,625 shares of company stock valued at $58,318,431 over the last 90 days. Corporate insiders own 0.61% of the company’s stock.

Several hedge funds have recently bought and sold shares of CVS. First Trust Advisors LP boosted its position in shares of CVS Health Corporation by 34.8% during the first quarter. First Trust Advisors LP now owns 739,753 shares of the pharmacy operator’s stock worth $58,071,000 after buying an additional 190,893 shares during the period. Meridian Management Co. boosted its position in shares of CVS Health Corporation by 19.0% during the first quarter. Meridian Management Co. now owns 24,585 shares of the pharmacy operator’s stock worth $1,930,000 after buying an additional 3,925 shares during the period. Investment Management of Virginia LLC boosted its position in shares of CVS Health Corporation by 41.2% during the first quarter. Investment Management of Virginia LLC now owns 33,060 shares of the pharmacy operator’s stock worth $2,595,000 after buying an additional 9,651 shares during the period. Copeland Capital Management LLC boosted its position in shares of CVS Health Corporation by 244.3% during the first quarter. Copeland Capital Management LLC now owns 105,559 shares of the pharmacy operator’s stock worth $8,553,000 after buying an additional 74,896 shares during the period. Finally, DekaBank Deutsche Girozentrale boosted its position in shares of CVS Health Corporation by 4.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 393,629 shares of the pharmacy operator’s stock worth $31,093,000 after buying an additional 16,525 shares during the period. 81.46% of the stock is owned by institutional investors.

About CVS Health Corporation

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health Corporation (NYSE:CVS)

Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.